Population-based study of medulloblastoma: Outcomes in Alberta from 1975 to 1996

Canadian Journal of Neurological Sciences

Volumn 35, Issue 2, 2008, Pages 210-215

  Roldán, Gloria ^a,b,c   Brasher, Penny ^b,d   Vecil, Giacomo ^e   Senger, Donna ^a,b   Rewcastle, Barry ^a   Cairncross, Gregory ^a,b,c   Forsyth, Peter ^a,b,c,f   Hamilton, Mark ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Heritage Medical Research Building ^*  (Canada)

^c Clark Smith Integrated Brain Tumor Research Centre   (Canada)

^d Division of Population Health and Information   (Canada)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f Health Research Innovation Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANADA; CANCER CLASSIFICATION; CANCER REGISTRY; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOLOGY; HUMAN; IMAGING; INCIDENCE; MALE; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TUMOR RECURRENCE;

EID: 45149124635     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100008659     Document Type: Article

References (47)

1. Cumberlin RL, Luk KH, Wara WM, Sheline GE, Wilson CB. Medulloblastoma: treatment results and effect on normal tissues. Cancer. 1979;43:1014-20.
2. Miltenburg D, Louw DF, Sutherland GR. Epidemiology of childhood brain tumors. Can J Neurol Sci. 1996;23:118-22.
3. Carrie C, Lasset C, Blay JY, Nrgrier S, Bouffet E, Barbet N, et al. Medulloblastoma in adults: survival and prognostic factors. Radiother Oncol. 1993;29:301-7.
4. Brandes AA, Paris MK. Review of the prognostic factors in medulloblastoma of children and adults. Crit Rev Oncol Hematol. 2004;5:121-8.
5. Herrlinger U, Steinbrecher A, Rieger J, Hau P, Kortmann RD, Meyermann R, et al. Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol. 2005;252(3):291-9.
6. Eisenstat DD. Clinical management of medulloblastoma in adults. Expert Rev Anticancer Ther. 2004;4:795-802.
7. Kopelson G, Linggood RM, Kleinman GM. Medulloblastoma in adults: improved survival with supervoltage radiation therapy. Cancer. 1982;49:1334-7.
8. Ribi K, Relly C, Landolt MA, Alber FD, Boltshauser E, Grotzer MA. Outcome of medulloblastoma in children long-term complications and quality of life. Neuropediatrics. 2005;36:357-65.
9. Rutkauskiene G, Labanauskas L, Jarusevicius L. The results of the treatment of childhood medulloblastoma with radiotherapy at Kaunas University of Medicine Hospital in 1994-2000. Medicina (Kaunas). 2006; 42:22-32.
10. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813-20.
11. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202-8.
12. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23:7621-31.
13. Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005;23:5511-19.
14. Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6:573-80.
15. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352:978-86.
16. Collins VP. Wilms' tumor: its behavior and prognosis. J Louisiana State Med Soc. 1955;107:474-80.
17. Brown WD, Tavare CJ, Sobel EL, Gilles FH. The applicability of Collins' Law to childhood brain tumors and its usefulness as a predictor of survival. Neurosurgery. 1995;36:1093-6.
18. Paulino AC. Collins' law revisited: can we reliably predict the time to recurrence in common pediatric tumors? Pediatr Hematol Oncol. 2006;23(1):81-6.
19. Brown WD, Tavare J, Sobel EL, Gilles FH. Medulloblastoma and Collin's law: a critical review of the concept of a period of risk for tumor recurrence and patient survival. Neurosurgery. 1995;36:691-7.
20. Lefkowithz IB, Packer RJ, Ryan SG, Shah N, Alavi J, Rorke LB, et al. Late recurrence of primitive neuroectodermal tumor/medulloblastoma. Cancer. 1988; 62(4):826-30.
21. World Health Organization, editors. International classification of diseases for oncology (ICD-0) 2. 1990 Geneva: World Health Organization.
22. World Health Organization, editors. International classification of diseases 9th revision clinical modification (ICD-9-CM) 8. 1991 Geneva: World Health Organization.
23. Cancer Programs Regulation. Alberta Reg. 242/1998. Database online. [updated 2006 September 26; cited 2006 October 10] Available from http://www.canlii.org/ab/laws/regu/1998r.242/20060926/whole.html.
24. Burger PC, Scheithauer BW. Tumors of the nervous system, 3rd series. Washington D.C: Armed Forces Institute of Pathology;1994.
25. Le QT, Weil MD, Wara WM, Lamborn KR, Prados MD, Edwards MS, et al. Adult medulloblastoma: an analysis of survival and prognostic factors. Cancer J Sci Am. 1997;3:238-45.
26. Chang CH, Housepian EM, Herbert C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastoma. Radiology. 1969;93:1351-9.
27. Kaplan EL, Meier P. "Nonparametric estimation from incomplete observations." J Am Stat Assoc. 1958; 53:457-81.
28. Mantel N. The detection of disease clustering and a generalized regression approach. Cancer Res. 1967;27:209-20.
29. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurgery. 1998;88:1-10.
30. Farwell JR, Dohrmann GJ, Flannery JT. Medulloblastoma in childhood: an epidemiological study. J Neurosurgery. 1984;61:657-64.
31. Agerlin N, Gjerris F, Brincker H, Haase J, Laursen H, Moller KA, et al. Childhood medulloblastoma in Denmark 1960-1984. A population-based retrospective study. Childs Nerv Syst. 1999;15(1):29-36.
32. Alston RD, Newton R, Kelsey A, Newbould MJ, Birch JM, Lawson B, et al. Childhood medulloblastoma in northwest England 1954 to 1997: incidence and survival. Dev Med Child Neurol. 2003;45(5):308-14.
33. Nishio S, Morioka T, Takeshita I, Fukui M. Medulloblastoma: survival and late recurrence after the Collins' risk period. Neurosurg Rev. 1997;20(4):245-9.
34. Bloom HJG, Bessell EM. Medulloblastoma in adults: a review of 47 patients treated between 1952 and 1981. Int J Radiat Oncol Biol Phys. 1990;18:763-72.
35. Akay KM, Izci Y, Baysefer A, Atabey C, Kismet E, Timurkaynak E. Surgical outcomes of cerebellar tumors in children. Pediatr Neurosurg. 2004;40:220-5.
36. Tabori U, Sung L, Hukin J, Laperriere N, Crooks B, Carret AS, et al. Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. Int J Radiat Oncol Biol Phys. 2006;64(2):402-7.
37. Robert RO, Lynch CF, Jones MP, Hart MN. Medulloblastoma: a population based study of 532 cases. J Neuropathol Exp Neurol. 1991;50:134-44.
38. Cogen PH, MacDonald JD. Tumor suppressor genes and medulloblastoma. J Neurooncology. 1996;29:103-12.
39. Malkin D, Li FP, Strong LC, Fraumeni JJ, Nelson CE, Kin DH, et al. Germline p53 mutations in a familial syndrome of breast cancer, and other neoplasms. Science. 1990;250: 1233-8.
40. Uziel T, Zindy F, Xie S, Lee Y, Forget A, Magdaleno S, et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev. 2005;19:2656-7 .
41. Badiali M, Pession A, Basso G, Andreini L, Rigobello L, Gallassi E, et al. N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of a particularly aggressive behavior of a tumor with c-myc amplification. Tumor. 1991;77:118-21.
42. Tomlinson FH, Jenkins RB, Scheithauer BW, Keelan PA, Ritland S, Parisi JE, et al. Aggressive medulloblastoma with high-level N-myc amplification. Mayo Clinic Proceed. 1994;69:359-65.
43. Kozmik Z, Sure U, Ruedi D, Busslinger M, Aguaai A. Deregulated expression of PAX5 in medulloblastoma. Proc Nat'l Acad Sci USA. 1995;92:5709-13.
44. Groodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science. 1997;277:1109-13.
45. Grotzer MA, Janss AJ, Fung KM, Biegel JA, Sutton LN, Rorke LB, et al. Trk C expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol. 2000;18:1027-35.
46. Pan E, Pellarin M, Holmes E, Smirnov I, Misra A, Eberhart CG, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res. 2005;11:4733-40.
47. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924-31.